Literature DB >> 3028795

Purification and biochemical characterization of the complete structure of a proteolytically modified beta-2-microglobulin with biological activity.

M H Nissen, L Thim, M Christensen.   

Abstract

A modified form of beta-2-microglobulin (beta-2-m) has previously been described to be present in serum from patients suffering from autoimmune diseases, acquired immune deficiency syndrome and small-cell lung cancer [Plesner, T. and Wiik, A. (1979) Scand. J. Immunol. 9, 247-254; Bhalla et al. (1985) Clin. Chem. 31, 1411-1412; Nissen et al. (1984) Clin. Chim. Acta 141, 41-50]. In the present study we describe the purification and characterization of this modified human serum beta-2-m from patients with small-cell lung cancer. Purified urinary beta-2-m was added to the serum samples incubated at 20 degrees C for five days to obtain a higher yield of modified beta-2-m (m-beta-2-m). m-beta-2-m was then purified from serum by gel filtration followed by chromatofocusing of the fractions containing beta-2-m. m-beta-2-m was found to have an apparent molecular mass of 15 kDa and a pI of 5.3 when analyzed by sodium dodecyl sulphate/polyacrylamide gel electrophoresis and analytical isoelectric focusing respectively. Amino acid analysis of m-beta-2-m revealed that the protein is missing one lysine residue compared to the composition deduced from the cDNA sequence of beta-2-m. Amino acid sequence analysis showed that m-beta-2-m consists of two polypeptide chains produced by a proteolytic cleavage of beta-2-m in the disulphide loop. After reduction and alkylation of m-beta-2-m the two chains were separated by reverse-phase high-pressure liquid chromatography. By amino acid sequencing, amino acid residues 1-56 and 59-99 were identified in the A and B chains respectively. By comparison of the amino acid composition of m-beta-2-m with the known sequence of beta-2-m it was possible to deduce the existence of a Ser-57 in the A chain. Thus proteolytic cleavage of beta-2-m in the intrachain disulphide loop releases the amino acid Lys-58, which results in a modified form of beta-2-m with a molecular mass of 11,620 Da as determined by amino acid analysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028795     DOI: 10.1111/j.1432-1033.1987.tb10731.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines.

Authors:  S S Ottesen; V Ahrenkiel; J Kieler
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Acute anterior uveitis and HLA-B27.

Authors:  P J Derhaag; T E Feltkamp
Journal:  Int Ophthalmol       Date:  1990-01       Impact factor: 2.031

3.  Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis.

Authors:  Sofia Giorgetti; Monica Stoppini; Glenys A Tennent; Annalisa Relini; Loredana Marchese; Sara Raimondi; Maria Monti; Sara Marini; Ole Østergaard; Niels H H Heegaard; Piero Pucci; Gennaro Esposito; Giampaolo Merlini; Vittorio Bellotti
Journal:  Protein Sci       Date:  2007-02       Impact factor: 6.725

4.  Excess-substrate inhibition in enzymology and high-dose inhibition in pharmacology: a reinterpretation [corrected].

Authors:  P W Kühl
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

5.  Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms.

Authors:  Olgica Trenchevska; Elena Kamcheva; Dobrin Nedelkov
Journal:  J Proteome Res       Date:  2010-09-23       Impact factor: 4.466

6.  Rheumatoid factors from patients with rheumatoid arthritis react with Des-Lys58-beta 2m, modified beta 2-microglobulin.

Authors:  R C Williams; M H Nissen; C C Malone
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

7.  Molecular variants of beta 2-microglobulin in renal insufficiency.

Authors:  C Vincent; L Dennoroy; J P Revillard
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.